- Indication: Psoriatic Arthritis
- Enrollment Status: Enrollment Open
- Protocol: CNTO1959PSA4002-STAR
- Drug: Guselkumab
- Sponsor: Janssen
- Description: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease
